S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:BLUE

bluebird bio (BLUE) Stock Price, News & Analysis

$1.25
+0.07 (+5.93%)
(As of 02/23/2024 ET)
Today's Range
$1.17
$1.32
50-Day Range
$0.91
$3.05
52-Week Range
$0.88
$5.53
Volume
11.45 million shs
Average Volume
7.41 million shs
Market Capitalization
$136.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.72

bluebird bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
437.7% Upside
$6.72 Price Target
Short Interest
Bearish
25.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of bluebird bio in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$29,961 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.77) to ($1.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

382nd out of 943 stocks

Biological Products, Except Diagnostic Industry

53rd out of 153 stocks


BLUE stock logo

About bluebird bio Stock (NASDAQ:BLUE)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

BLUE Stock Price History

BLUE Stock News Headlines

Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
bluebird bio Stock (NASDAQ:BLUE) Insider Trades
Billionaires Are Now FLOODING Into Gold
Ray Dalio, John Paulson, and many others all recommend you own gold right now. But did you know there's another huge investor (worth more than all the world's billionaires COMBINED) buying gold by the ton? That's why the best move to make right now could be this little-known gold investment (which you can get started with for just $5).
Regeneron to acquire 2seventy’s cell therapy pipeline
Bluebird Bio: Innovative Therapies, Monetary Setbacks
Hold Rating on Bluebird Bio Amid Launch Optimism and Financial Prudence
William Blair Reaffirms Their Hold Rating on Bluebird Bio (BLUE)
Why bluebird (BLUE) Stock Might be a Great Pick
Bluebird Bio Shares Fall 45% On Stock Offering
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
2/24/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
323
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.72
High Stock Price Target
$13.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+437.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

Net Income
$-266,580,000.00
Net Margins
-419.64%
Pretax Margin
-419.50%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$2.37 per share

Miscellaneous

Free Float
107,040,000
Market Cap
$136.68 million
Optionable
Optionable
Beta
0.68
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Andrew ObenshainMr. Andrew Obenshain (Age 50)
    President, CEO & Director
    Comp: $1.04M
  • Mr. Thomas J. Klima (Age 52)
    Chief Commercial Officer & COO
    Comp: $654.97k
  • Mr. Richard A. Colvin M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $696.24k
  • Mr. Christopher Krawtschuk CPA (Age 50)
    CFO, Principal Accounting Officer & Treasurer
  • Mr. Joseph D. Vittiglio Esq. (Age 52)
    J.D., Chief Legal & Business Officer and Secretary
  • Jess Rowlands
    Head of Corporate Communications
  • Ms. Andrea Walton
    Chief People Officer
  • Mr. Kasra Kasraian
    Senior Vice President of Technical Development & Operations
  • Mr. Scott Shoemaker
    Senior Vice President of Quality
  • Ms. Sarah Alspach
    Senior Vice President of External Affairs














BLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price target for 2024?

12 Wall Street research analysts have issued twelve-month target prices for bluebird bio's stock. Their BLUE share price targets range from $3.00 to $13.00. On average, they anticipate the company's share price to reach $6.72 in the next twelve months. This suggests a possible upside of 437.7% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2024?

bluebird bio's stock was trading at $1.38 at the start of the year. Since then, BLUE shares have decreased by 9.4% and is now trading at $1.25.
View the best growth stocks for 2024 here
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) issued its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.03. The biotechnology company earned $12.40 million during the quarter, compared to analyst estimates of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. bluebird bio's revenue was up 17364.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.92) earnings per share.

What ETFs hold bluebird bio's stock?
What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.03%), Granahan Investment Management LLC (7.39%), Norges Bank (3.65%), Palo Alto Investors LP (3.05%), Ghisallo Capital Management LLC (2.88%) and Dimensional Fund Advisors LP (2.74%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLUE) was last updated on 2/25/2024 by MarketBeat.com Staff